Rheumatoid Arthritis Clinical Trial
— RAOfficial title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults With Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate
Verified date | September 2015 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to assess whether BMS-817399 in combination with Methotrexate is effective in treating moderate to severe rheumatoid arthritis.
Status | Completed |
Enrollment | 123 |
Est. completion date | February 2013 |
Est. primary completion date | February 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Male or female subjects, 18 years of age or older, with rheumatoid arthritis (RA) for at least 6 months prior to screening - Subjects must have a tender joint count of at least 6 (28 joint count), swollen joint count of at least 6 (28 joint count) at screening. All subjects must have clinical evidence of synovitis in one hand/wrist at screening - Serum C-reactive protein (hsCRP) above upper limits of normal at screening - Subjects must have been treated with and tolerated Methotrexate (MTX) therapy at a weekly oral or parenteral dose = 10 mg for = 4 months prior to screening. Dose must be stable, with no change in route of administration, for = 6 weeks prior to randomization. A MTX weekly dose as low as 7.5 mg is permitted if intolerance to doses =10 mg has been documented in the subject's medical history - Subjects must be receiving folic acid, folinic acid, or leucovorin supplementation at a stable dose for at least 4 weeks prior to randomization - Subjects who were previously treated with up to two tumor necrosis factor a (TNF-a) inhibitors - If taking antimalarials (e.g. hydroxychloroquine or chloroquine), subject must have been on a stable dose for = 4 months prior to randomization - If taking non-steroidal anti-inflammatory drugs (NSAIDs), subjects must have been on stable doses for = 2 weeks prior to randomization - If taking oral corticosteroids, daily doses must be = 10 mg/day of prednisone or equivalent and stable for = 4 weeks before randomization - Subject is willing to participate to the study and has signed the informed consent prior to undergoing any screening procedures - Women of childbearing potential (WOCBP) and men must agree to use at least two acceptable methods to avoid pregnancy for the entire study period and until 60 days (for women) and 90 days (for men) after the last dose of BMS-817399. WOCBP must have a negative urine pregnancy test at screening, randomization and at scheduled visits throughout the study Exclusion Criteria: - Arthritis onset prior to 16 years of age or subjects with documented juvenile RA - Subjects who are bed- or wheelchair-bound - Subjects with other autoimmune diseases or arthritis syndromes - Women who are pregnant, breastfeeding or with a positive pregnancy test at screening or prior to randomization - Subjects who have any condition that could impact upon the absorption of study drug (i.e., gastric stapling, duodenal surgery, malabsorption syndrome) - Subjects with a history of, or a concurrent severe, progressive, or uncontrolled disease (other than RA) that in the opinion of the investigator might place the subject at unacceptable risk for participation in this study - Subjects who have present or previous (last 5 years) malignancies, except history of cured squamous or basal skin cell carcinoma or cured breast or cervical cancer - Subjects at risk for tuberculosis (TB) or with evidence of TB clinical history, chest X rays or tuberculin skin test - Subjects with evidence of active or latent bacterial or viral infections (including human immunodeficiency virus); Positive blood screen for hepatitis B surface antigen or hepatitis C antibody - Subjects with any serious bacterial infection within the last 2 months, unless treated and resolved with antibiotics - Subjects who have clinically significant drug or alcohol abuse or known cirrhosis including alcoholic cirrhosis - If a subject has received any of the following treatments, the indicated washout period prior to randomization must be followed: 1. Oral or injectable azathioprine, gold, D-Penicillamine, cyclosporine, anakinra, etanercept, parenteral or intra-articular corticosteroids: 30 days 2. Leflunomide: 6 months unless an active washout with Cholestyramine has been performed 3. Mycophenolate mofetil, cyclophosphamide, tacrolimus or other immunosuppressant: 3 months 4. Adalimumab, Infliximab, Golimumab, Certolizumab pegol, Abatacept or Tocilizumab: 60 days 5. Rituximab or any B-cell depleting agent: 1 year - Use CYP3A4 inhibitors or inducers during the study - Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 1.5x upper limit of normal (ULN), total bilirubin = 1.4x ULN, estimated glomerular filtration rate (GFR) < 50 mL/min/1.73m2, hemoglobin < 10.0 g/dL, white blood cell count < 3,500/mm3, absolute neutrophil count < 1,700/mm3 or platelets < 125,000/mm3 |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Argentina | Local Institution | Buenos Aires | |
Argentina | Local Institution | Buenos Aires | |
Argentina | Local Institution | Capital Federal | Buenos Aires |
Argentina | Local Institution | Tucuman | |
Korea, Republic of | Local Institution | Daegu | |
Korea, Republic of | Local Institution | Gwangju | |
Korea, Republic of | Local Institution | Seoul | |
Korea, Republic of | Local Institution | Seoul | |
Mexico | Local Institution | D.f. | Distrito Federal |
Mexico | Local Institution | Guadalajara | Jalisco |
Mexico | Local Institution | Guadalajara | Jalisco |
Mexico | Local Institution | Guadalajara | Jalisco |
Mexico | Local Institution | Merida | Yucatan |
Mexico | Local Institution | San Luis Potosi | |
Mexico | Local Institution | Tijuana | Baja California |
Russian Federation | Local Institution | Moscow | |
Russian Federation | Local Institution | Yaroslavl | |
South Africa | Local Institution | Durban | Kwa Zulu Natal |
South Africa | Local Institution | Panorama | Western Cape |
South Africa | Local Institution | Pinelands | Western Cape |
South Africa | Local Institution | Pretoria | Gauteng |
Spain | Local Institution | Cordoba | |
Spain | Local Institution | Santiago De Compostela | |
Spain | Local Institution | Sevilla | |
United States | Altoona Center For Clinical Research | Duncansville | Pennsylvania |
United States | Pharma Resource | East Providence | Rhode Island |
United States | Paramount Medical Research & Consulting, Llc | Middleburg Heights | Ohio |
United States | Desert Medical Advances | Palm Desert | California |
United States | Sarasota Arthritis Research Center | Sarasota | Florida |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States, Argentina, Korea, Republic of, Mexico, Russian Federation, South Africa, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP) change from baseline of BMS-817399 versus placebo | Baseline and at 12 weeks | No | |
Secondary | Safety assessments will be based on adverse event reports and the results of vital sign measurements, electrocardiogram, physical examinations, and clinical laboratory tests | 16 weeks | Yes | |
Secondary | Proportion of subjects achieving 20% American College of Rheumatology (ACR) response in each treatment group | Day 15 | No | |
Secondary | Proportion of subjects achieving 20% ACR response in each treatment group | Day 29 | No | |
Secondary | Proportion of subjects achieving 20% ACR response in each treatment group | Day 57 | No | |
Secondary | Proportion of subjects achieving 20% ACR response in each treatment group | Day 85 | No | |
Secondary | Proportion of subjects achieving 50% ACR response in each treatment group | Day 15 | No | |
Secondary | Proportion of subjects achieving 50% ACR response in each treatment group | Day 29 | No | |
Secondary | Proportion of subjects achieving 50% ACR response in each treatment group | Day 57 | No | |
Secondary | Proportion of subjects achieving 50% ACR response in each treatment group | Day 85 | No | |
Secondary | Proportion of subjects achieving 70% ACR response in each treatment group | Day 15 | No | |
Secondary | Proportion of subjects achieving 70% ACR response in each treatment group | Day 29 | No | |
Secondary | Proportion of subjects achieving 70% ACR response in each treatment group | Day 57 | No | |
Secondary | Proportion of subjects achieving 70% ACR response in each treatment group | Day 85 | No | |
Secondary | Percent change from baseline in disability index of the Health Assessment Questionnaire (HAQ-DI) | Baseline and Day 15 | No | |
Secondary | Percent change from baseline in disability index of the Health Assessment Questionnaire (HAQ-DI) | Baseline and Day 29 | No | |
Secondary | Percent change from baseline in disability index of the Health Assessment Questionnaire (HAQ-DI) | Baseline and Day 57 | No | |
Secondary | Percent change from baseline in disability index of the Health Assessment Questionnaire (HAQ-DI) | Baseline and Day 85 | No | |
Secondary | To assess the minimum observed concentration (Cmin) of BMS-817399 | Day 15, Day 29, Day 57 and Day 85 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |